However, Raymond James analysts have recently shown optimism for Supermicro stock. Is this a good time to buy? Let’s find out. Raymond James initiated Supermicro stock coverage, rating it ...

Investing.com -- Raymond James downgraded Apellis Pharmaceuticals (NASDAQ:APLS) to Outperform from Strong Buy following a first-quarter sales miss and rising concerns over volatility in the ...

Raymond James & Associates Inc. successfully hosted its Inaugural Micronesia Investment and Retirement Plans Conference for its clients in the region, bringing together a distinguished lineup of ...

Supermicro shares surged Tuesday after Raymond James initiated coverage of the company with a bullish rating. The AI server maker has "emerged as a market leader," the analysts said. Even with ...

Raymond James has initiated coverage on Super Micro Computer SMCI with an Outperform rating. This move comes in light of Supermicro’s strong standing in the AI-optimized infrastructure sector ...

On May 21, Raymond James Financial, Inc. (NYSE:RJF) announced a quarterly cash dividend of $0.50 per share, payable on July 15, 2025, to shareholders recorded as of July 1, 2025. The financial ...

Raymond James analysts revised their 2025 earnings estimate for the S&P 500 (SP500) downward from $270 to approximately $250-255 due to expected reduced economic activity. They maintained their ...

New advisors have joined Raymond James and NewEdge Wealth in the latest reported moves. At NewEdge Wealth, Jesse Christensen transitions to the firm from NewEdge Advisors having grown his Hudson ...

On Thursday, Raymond James analyst Andrew Marok reaffirmed a positive outlook on Nexxen (NASDAQ:NEXN), maintaining an Outperform rating with a $15.00 price target. According to InvestingPro data ...

Raymond James landed a big one this week with a financial firm moving its $2.7 billion AUM wealth business over from LPL Financial. But LPL wasn't only on the losing end. It picked up teams from ...

On Friday, Raymond James analysts adjusted their stance on Profound Medical Corp. (NASDAQ:PROF), downgrading the company’s stock rating from Strong Buy to Outperform and lowering the price ...